Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

Roche gets EU okay for Avastin/Tarceva combination

Roche gets EU okay for Avastin/Tarceva combination Avastin targets VEGF while Tarceva is an EGFR inhibitor - pathways known to be drivers of tumour growth - and both are already approved individually as NSCLC therapies. ... Patients given the combination lived without disease progression for a median of

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer The two-stage trial of patritumab (U3-1287/AMG 888) in combination with Roche's EGFR inhibitor Tarceva (erlotinib) patients with non-small cell lung cancer (NSCLC) was stopped on the

FDA approves expanded indication for Gilotrif

FDA approves expanded indication for Gilotrif It showed Gilotrif achieved its primary objective of significantly improving progression-free survival when compared against Roche/Astellas' Tarceva (erlotinib).

FDA panel says no to quick approval of Clovis' rociletinib

FDA panel says no to quick approval of Clovis' rociletinib The drug is a third-generation EGFR inhibitor designed for use when other drugs in the class - Roche/Astellas' market-leading Tarceva (erlotinib), AstraZeneca's Iressa (gefitinib) and Boehringer Ingelheim's

Boehringer's Giotrif wins new NSCLC licence in Europe

Boehringer's Giotrif wins new NSCLC licence in Europe Giotrif reached its primary endpoint in the study of significantly delaying the progression of SqCC of the lung when compared against Roche/Astellas' Tarceva (erlotinib). ... year. Giotrif joins several EGFR-targeting therapies on the market, including

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics